Long-term outcome with clozapine: Comparison of patients continuing and discontinuing treatment

International Clinical Psychopharmacology

Volumn 13, Issue 2, 1998, Pages 75-78

  Laker, M K ^a,b   Duffett, R S ^a   Cookson, J C ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Knowle Hospital   (United Kingdom)

Author keywords

Clozapine; Hospitalization; Naturalistic survey; Outcome

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; INSTITUTIONAL CARE; LONG TERM CARE; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031959584     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803000-00003     Document Type: Article

References (18)

1. Atkin K, Kendall F, Gould D, Freeman H, Lieberman J, O'Sullivan D (1996). Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169:483-488.
2. Avnon M, Rabinowitz J (1995). Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. Br J Psychiatry 167:760-764.
3. Baldessarini RJ, Frankenburg FR (1991). Clozapine: a novel antipsychotic agent. N Engl J Med 324:746-754.
4. British National Formulary (1997). 33:163.
5. Chow EW, Collins EJ, Nuttall SE, Bassett AS (1995). Clinical use of clozapine in a major urban setting: one year experience. J Psychiatry Neurosc 20:133-140.
6. Clozapine Study Group (1993). The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 163:150-154.
7. Davies LM, Drummond MF (1993). Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 162:38-42.
8. Essock SM, Hargreaves WA, Covell NH, Goethe J (1996). Antipsychotics in research and clinical settings: clozapine's effectiveness for patients in state hospitals: results from a randomised trial. Psychopharmacol Bull 32:683-697.
9. Fischer-Cornelssen KA, Ferner UJ (1976). An example of European multicentre trials: multispectral analysis of clozapine. Psychopharmacol Bull 12:34-39.
10. Fischer-Cornelssen KA, Ferner UJ, Steiner H (1974). Multifokale Psychopharmakaprufung. Arzneimittelforschung 24:1706-1724.
11. Kane JM, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
12. Lindstrom LH (1988). The effect of long-term treatment with Clozapine in schizophrenia: retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77:524-529.
13. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B (1993). Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 150:1630-1638.
14. Naber D, Holzbach R, Perro C, Hippius H (1992). Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160 (suppl. 17):54-59.
15. Reid WH, Mason M, Toprac M (1994). Savings in hospital bed-days related to treatment with clozapine. Hosp Commun Psychiatry 45:261-264.
16. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA (1990). Cost effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Commun Psychiatry 41:850-854.
17. Seabourne A, Thomas CS (1994). The use of clozapine in South Manchester. Psychiatr Bull R Coll Psychiatrists 18:618-619.
18. Zito JM, Volavka J, Craig TJ, Czobor P, Banks S, Vitrai J (1993). Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Ann Pharmacother 27:1262-1269.